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Abstract Alcohol affects the transmission and treatment
of HIV, yet may be under-reported in resource-limited
settings. We compared self-reported alcohol consumption
with levels of plasma carbohydrate-deficient transferrin
(%CDT), a biomarker of heavy alcohol consumption, in
persons initiating antiretroviral therapy in Uganda. Almost
seven percent (6.7%) of persons reporting abstaining and
10% reporting consuming 1–40 drinks in the prior month
tested positive for %CDT, and actual under-report may be
higher due to low sensitivity of %CDT. These results
suggest likely under-report in those reporting abstaining
and current drinking. Improved identification of heavy
alcohol consumption is needed for research and clinical
purposes.
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Introduction
Alcohol consumption has a substantial harmful impact on
the HIV epidemic in sub-Saharan Africa. Alcohol con-
sumption has been a consistent risk factor for HIV
acquisition in this region [1] and is associated with
decreased antiretroviral therapy (ART) adherence world-
wide [2]. In addition, many authors have hypothesized a
link between alcohol consumption and HIV disease pro-
gression [3].
Uganda has an HIV prevalence of 5.4% and one of the
highest per capita volumes of consumption of alcohol in
the world. The per capita adult alcohol consumption is
estimated to be 18.6 l of pure alcohol per year [4]. Almost
one quarter (23.8%) of men and 7.0% of women report
typically drinking five or more drinks per drinking occa-
sion at least once a month in the prior year [4]. However,
self-reported recent heavy alcohol consumption in a
sample of HIV-positive persons initiating ART in Uganda
was quite low, with only 3% reporting typically drinking
six or more drinks per drinking occasion at least once a
month in the prior year [5]. If alcohol consumption is
under-reported in the setting of HIV, then the true mag-
nitude of the effect of alcohol on the HIV epidemic in
sub-Saharan Africa will be undetected or under-estimated.
In addition, clinicians need to know about their patients’
alcohol consumption in order to assess potential barriers to
ART adherence.
Therefore, it is important to accurately assess the level
of alcohol consumption among HIV positive patients. The
goal of this study was to use a highly specific biochemical
marker of heavy alcohol consumption, carbohydrate-defi-
cient transferrin (CDT), to estimate the level of under-
reported heavy alcohol consumption among persons initi-
ating ART in Uganda.
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Methods
Study Subjects
From 2005 through 2009, 500 HIV-infected adults initiat-
ing ART were recruited from the Mbarara Regional
Referral Hospital Immune Suppression Syndrome (ISS)
Clinic in southwestern Uganda for a cohort study of HIV
treatment outcomes. Eligibility criteria included being at
least age 18, being willing to have serial blood draws and
at-home ART adherence monitoring, and having received a
prescription to initiate ART in the next week. For this
analysis, we conducted CDT testing on stored plasma for
all subjects in the cohort who reported any alcohol con-
sumption in the prior year at baseline (37%) and for whom
there was sufficient archival plasma (61%). We addition-
ally selected a random sample of 54 subjects who reported
no alcohol consumption in the prior year (28% of those
with sufficient plasma).
All procedures were approved by the Institutional
Review Boards of the University of California, San Fran-
cisco, Partners HealthCare, and the Mbarara University of
Science and Technology.
Alcohol Assessment
Alcohol consumption was reported at baseline using the
World Health Organization Alcohol Use Disorders Iden-
tification Test (AUDIT), in addition to a question about
when, if ever, alcohol was last consumed; the number of
days in the prior 30 that alcohol was consumed; the typ-
ical number of standard drinks (14 grams of pure alcohol)
consumed per drinking day; and the total amount of
money spent on alcohol in the prior 30 days. The number
of drinks per drinking day was missing for those who
reported solely drinking beverages served in containers
from which the number of drinks could not be estimated
(n = 2, 1% of the sample). Other missing values are noted
in the table.
Carbohydrate-Deficient Transferrin (CDT)
Biochemical markers of alcohol consumption have shown
promise as objective measures of alcohol consumption.
CDT is an abnormal transferrin profile that is caused by
sustained heavy drinking [6]. While the results have varied,
CDT is typically elevated after 50–80 g of ethanol (i.e.,
3.5–6 US standard drink units) consumed daily or almost
daily over 14 days [7], with all but the heaviest drinkers
returning to normal after four weeks of abstinence [8].
Disialotransferrin is one of the minor glycoforms of human
transferrin, and the percentage of total CDT that is disi-
alotransferrin, as determined by high-performance liquid
chromatography (HPLC), is the recommended method for
measuring %CDT [9]. The percent of abstainers and
moderate drinkers combined that tested %CDT positive
(i.e., the percent false positive, or one minus the specificity
of the test) using a cutoff of 1.8% was 0% in Italy [10] and
Sweden [9] and 5.6% in a multi-national study [6]. In the
latter study, the specificity was 100% when moderate
drinkers were excluded, and the authors noted that errors in
self-report were likely among the moderate drinkers [6].
The sensitivity of %CDT for detecting heavy drinking at
the 1.8% cutoff in that study was 44.6%. Despite this low
sensitivity, we chose %CDT because of its high specificity
as well as its ability to be quantified in plasma. Other
candidate biomarkers include phosphatidylethanol, which
is highly sensitive and specific but currently only available
for testing in whole blood [11], and traditional markers
such as c-glutamyl transpeptidase and mean corpuscular
volume which are widely available but also lack sensitivity
[11], and are subject to alterations due to HIV disease and
ART use.
Laboratory Methods
Plasma was stored at -70C at the Makerere University—
Johns Hopkins University Research Collaboration Labo-
ratories and shipped on dry ice to the AIDS Specimen Bank
in San Francisco. We (Javors) conducted HPLC to detect
%CDT in stored plasma samples using the methods as
described by Helander et al. [9].
Statistical Analysis
We report the percent of participants with positive %CDT
tests (and exact binomial 95% confidence intervals) by the
duration since last consumed alcohol, and among those
reporting drinking alcohol in the prior 30 days, by the
following measures of drinking in the prior 30 days: the
number of days drinking, the typical number of drinks per
day, the total number of drinks, and the total amount of
money spent on alcohol. The total number of drinks was
calculated by multiplying the number of days drinking by
the typical number of drinks per day. We divided these
variables into heavy and not heavy categories at their 75th
percentile values as follows: drinking more than 15 days in
the prior month (yes/no), typically drinking more than four
drinks per occasion (yes/no), drinking more than 40 drinks
in the past month (yes/no), and spending 15,000 Uganda
Shillings (USH, 1 US dollar equaled approximately 1,600
USH during the study period) or more on alcohol in the
prior month (yes/no). We calculated exact 95% confidence
intervals for the proportion %CDT positive and conducted
Fisher exact tests to determine whether the proportion
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%CDT positive was associated with the drinking variables.
We performed the Breslow–Day test of homogeneity to test
for interaction by gender because previous research has
shown lower sensitivity for %CDT among females [6], and
concluded there was interaction if P \ 0.15.
Results
We tested plasma for 79 male (48.5%) and 84 female
(51.5%) participants, with median age 36 (range 20–66).
Overall, 6.7% (2.9–12.7%) of persons who reported
abstaining for 30 days or more tested %CDT positive
(Table 1). We divided the percent of %CDT positive
results by the reported sensitivity of the test (44.6%) to
back-calculate the percent of those reporting abstaining
who likely consumed heavy alcohol; this estimate is
15.0%.
Of the 43 who reported any alcohol consumption in the
prior 30 days, 7 (16.3%; 6.8–30.7%) tested positive.
Among current drinkers, there were significant associations
with %CDT and the number of days reported drinking, the
total number of drinks, and the amount of money spent
drinking (all Fisher’s exact test P \ 0.05), and a borderline
significant association with number of drinks per day
(Fisher’s exact test P = 0.09). There was no significant
interaction by sex (all Breslow–Day P [ 0.15).
Discussion
We used %CDT, a highly specific marker of heavy alcohol
consumption (i.e., one that would result in very few false
positives) and found that approximately 7% of self-repor-
ted abstainers were positive. Using the published sensitiv-
ity of %CDT, we estimate that the actual percent of those
reporting abstaining who consumed heavy alcohol was
15%.
Self-reported heavy alcohol consumption was confirmed
by positive %CDT in a high proportion of persons
reporting drinking frequently and/or a large number of
drinks. However, a substantial fraction of those reporting
few drinking days, light consumption on drinking days, or
low amounts of money spent on alcohol were also %CDT
positive, indicating that there are challenges to accurate
report of the level of drinking even among those willing to
report recent alcohol consumption.
Lower than expected self-reported alcohol consumption
in persons with HIV in Uganda may occur for several
reasons. First, standard measures of alcohol consumption
are based on reporting the frequency of consuming stan-
dard drink units which are problematic because neither
drink size nor alcohol content is standard in many places
[12], including Uganda. While commercially prepared
alcohol is available, much of the available alcohol is
brewed or distilled at home or locally, with variable alco-
hol concentrations. In addition, home or locally brewed or
distilled forms of alcohol can be obtained in varying con-
tainer sizes and may be consumed using long wooden or
plastic straws shared among several people at the pot side,
making it difficult to quantify consumption.
Second, social desirability bias may also cause under-
reporting if there is the perception of negative conse-
quences associated with reported use. Persons infected with
HIV may under-report their alcohol consumption if they
fear that they will be denied ART. HIV-infected patients in
Uganda, especially those initiating ART, are counseled to
abstain from drinking by clinic counselors.
Our study was limited by a modest sample size. In
addition, the lack of sensitivity of %CDT, the best com-
mercially available biomarker for testing of plasma, con-
strained the interpretation of the estimates. There is a small
chance of false positives, which would bias our estimates
upwards. In order to counteract this, we considered using a
higher cutoff value for %CDT positive. However,
increasing the %CDT cutoff from 1.8 to 2.0% resulted in
only a 1.5% gain in specificity accompanied by a 8.5%
decline in sensitivity in a recent study [6]. We recommend
that future studies collect whole blood in order take
advantage of the high sensitivity and specificity of phos-
phatidylethanol as a marker of heavy alcohol consumption
[11].
Table 1 Carbohydrate-deficient transferrin (%CDT) positive by self-
reported date of last consumption and measures of recent alcohol
consumption
n %CDT positive/N
(%; 95% exact binomial CI)
When last consumed alcohol
More than 30 days ago 8/120 (6.7%; 2.9–12.7%)
Within the past 30 days 7/43 (16.3%; 6.8–30.7%)
Prior 30 days alcohol consumption
Number of days drinking (n = 2 missing)
1–15 3/31 (9.7%; 2.0–25.8%)
16–30 4/10 (40.0%; 12.2–73.4%)
Typical number of drinks per drinking day (n = 2 missing,
n = 2 drank home brewed/distilled only)
1–4 4/32 (12.5%; 3.5–28.9%)
C5 3/7 (42.9%; 9.9–81.6%)
Total number of drinks (n = 4 missing)
1–40 3/30 (10.0%; 2.1–26.5%)
C41 4/9 (44.4%; 13.7–78.8%)
Total amount of money spent on alcohol (n = 3 missing)
\15,000 USH 2/30 (6.7%; 1.0–22.1%)
C15,000 USH 4/10 (40.0%; 12.2–73.4%)
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Improved measurement of alcohol exposure is important
to understand the effect of alcohol on HIV outcomes. For
example, studies of the effect of alcohol on HIV disease
progression have had mixed results [3], possibly due to
difficulties in measuring alcohol consumption. In addition,
clinicians treating HIV need to be able to assess the level of
alcohol consumption in their patients in order to consider
potential barriers to adherence. The implications of this
study are that researchers and clinicians should be aware
that a non-negligible proportion of persons with HIV in
Uganda under-report heavy alcohol consumption. This
study shows that heavy alcohol consumption is under-
reported via denial of any alcohol consumption and under-
report of the quantity of alcohol consumed. Under-report
can only be addressed by developing and implementing
sensitive and specific biologic markers of alcohol con-
sumption or devising methods that promote alcohol con-
sumption disclosure.
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